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The South African (SA) government is undertaking a massive 
roll-out of COVID-19 vaccination, with the aim of vaccinating at 
least 67% of the population in order to achieve herd immunity. 
Initially frontline healthcare workers are being vaccinated, followed 
by essential workers, individuals aged >60 years and adults with 
comorbid disease. This phased roll-out is designed to vaccinate those 
most at risk of contracting COVID-19, followed by those most at risk 
of severe disease.[1]
Pregnant women are at greater risk of severe COVID-19 than 
non-pregnant women, with increased rates of intensive care unit 
(ICU) admission, need for supplemental oxygen and invasive 
ventilation, and mortality.[2-5] These findings are in keeping with 
other viral pneumonias, such as influenza, where pregnant women 
are disproportionately affected and have higher morbidity and 
mortality compared with non-pregnant women.[6,7] Given the lack 
of safety data on vaccination in pregnancy, the SA government has 
recommended against vaccination in pregnant and breastfeeding 
women.[8] This is in contrast to the recommendations of a number of 
international societies.
COVID-19 in pregnancy
The altered immune system in pregnancy, with a shift towards a 
T-helper 2 response and humoral immunity, as well as a decrease 
in natural killer cells and circulating plasmacytoid dendritic cells, 
predisposes pregnant women with viral infections to severe disease.[9]
Despite early reports[10] of pregnant and non-pregnant women 
with COVID-19 showing no difference in disease severity, it is 
now clear that pregnancy is an independent risk factor for severe 
COVID-19. A number of studies[2-4] have shown that rates of ICU 
admission are higher in pregnant women with COVID-19 than in 
their non-pregnant counterparts, with 10.5 v. 3.9 cases per 1 000 
women, respectively, in a large report from the Centers for Disease 
Control and Prevention (CDC) in the USA.[2] Similarly, the need for 
endotracheal intubation was significantly higher in pregnant women 
compared with non-pregnant women with COVID-19 (10.16% v. 
1.67%, respectively),[4] and the need for invasive ventilation increased 
in pregnant women with COVID-19.[2,3]
Furthermore, the risk of mortality was shown to be 70% higher 
in pregnant women with COVID-19 compared with their non-
pregnant counterparts (1.5 v. 1.2 per 1 000 cases; adjusted risk ratio 
1.7, 95% confidence interval 1.2 - 2.4).[2] It has also been shown that 
the risk of mortality is significantly higher in pregnant women with 
than without COVID-19 (141 v. 5 deaths per 100 000 women).[5] 
Concerningly, data from both the USA and the UK have shown a 
disproportionate number of deaths in non-white women.[2,11]
COVID-19 infection in pregnant women also increases the risk 
of adverse pregnancy outcomes. The risk of thromboembolic events, 
including myocardial infarction and venous thromboembolism, as 
well as pre-eclampsia, is higher in pregnant women with COVID-19 
compared with those without.[5] COVID-19 in pregnancy appears to 
be associated with an increased risk of preterm delivery, with 22% of 
neonates born prematurely, compared with the US national average 
of 10%, in a large review.[12] Importantly, severity of disease seems to 
play a role, with preterm birth reported in 29% and 88% of pregnant 
women with severe disease and critical disease, respectively.[13] Rates 
of miscarriage also increase in pregnancies affected by COVID-19.[4,14]
COVID-19 in neonates
Intrauterine transmission of SARS-CoV-2 remains controversial. 
A number of cases supporting possible vertical transmission 
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have been reported,[15-18] but none of these meet the criteria for 
confirmed vertical transmission proposed by Shah et al.[19] Horizontal 
transmission of the virus is much more likely and can occur during 
vaginal delivery, via the faecal-oral route, or later through close 
contact with an infected mother during nursing.[20] Despite this, the 
benefits of breastfeeding outweigh the risk of transmission of the 
virus through breastmilk, with some reporting that breastmilk may 
contain anti-SARS-CoV-2 antibodies.[21]
A prospective population-based cohort study in the UK showed 
an incidence of confirmed COVID-19 in neonates of 5.6 per 100 000. 
The majority of neonates (68%) were diagnosed >7 days after birth, 
suggesting that horizontal transmission is more likely than vertical 
exposure.[15] While neonates of mothers with COVID-19 rarely acquire 
the disease and hospital admission is uncommon, neonates who do 
become infected are at risk of severe disease. In the cohort study 
mentioned above, severe disease occurred in 42% of cases, 36% received 
ICU care and 33% required respiratory support.[15] Furthermore, the 
long-term effects of COVID-19 acquired in the neonatal period are 
unknown, and ongoing research in this area is crucial.[15,21]
Available COVID-19 vaccines
Various COVID-19 vaccines that utilise different vaccine platforms 
are available worldwide or are in advanced-stage clinical trials 
(Table 1).[22] The SA government has committed to source vaccines 
from a combination of vaccine suppliers, but as of 15 March 2021, 
only the AstraZeneca/University of Oxford ChAdOx1 nCov-19 
AZD1222 vaccine (AstraZeneca) had been granted authorisation for 
commercial use by the South African Health Products Regulatory 
Authority (SAHPRA). The Pfizer-BioNTech BNT-162b2 (Pfizer) 
and Johnson & Johnson/Janssen AD26.COV2.S (J&J) vaccines are 
currently under review at SAHPRA, and the J&J vaccine is being 
rolled out to healthcare workers as part of the Sisonke open-
label implementation trial.[23] The Novavax NVX-CoV2373 vaccine 
(Novavax) has demonstrated efficacy in a recent phase 3 trial in 
SA and could potentially be available in the near future. Each of 
these vaccines utilises a different vaccine platform with unique 
considerations for use in pregnant women.
Viral vector vaccines
The AstraZeneca and J&J vaccines both use adenoviruses as 
the vector for delivery of SARS-CoV-2 viral proteins in order 
to induce protective immune responses.[22] The AstraZeneca 
vaccine uses a chimpanzee adenovirus vector and the J&J vaccine 
a recombinant human adenovirus serotype 26 (Ad26) vector. 
Both vaccine platforms have been used in vaccines against other 
viruses, including HIV, Ebola, Zika and respiratory syncytial 
virus (RSV).[24,25] A frequently expressed concern regarding the 
use of adenovirus vectors in pregnant women is the theoretical 
potential for adenovirus vector infection of the fetus. This concern 
is unfounded, as both adenovirus vectors are attenuated viruses 
that are replication incompetent. This means that these vectors 
can infect human cells following inoculation but cannot replicate 
in those cells, thereby delivering SARS-CoV-2 viral proteins to the 
mother without transfer of the viral vector to the fetus. Studies in 
animal models using adenovirus vectors have shown no adverse 
effect in pregnancy, but clinical trials of these vaccines in humans 
so far have excluded pregnant women.[26,27]
mRNA vaccines
The Pfizer and Moderna mRNA-1273 (Moderna) vaccines employ 
a novel vaccine technology based on mRNA.[28,29] Both of these 
vaccines encode SARS-CoV-2 genetic information in the form 
of RNA packaged into lipid nanoparticles that, when injected, 
enter the cells of the vaccinated individual, causing SARS-CoV-2 
antigens to be expressed on the cell surface.[22] Host immune cells 
recognise these antigens and mount an immune response. Common 
misconceptions include that the mRNA can alter the DNA of the 
vaccinated individual and that the mRNA may be passed on to the 
fetus, with potential harmful consequences. However, the mRNA 
does not enter the nucleus of the cell and therefore cannot alter the 
cell’s DNA.[30] In addition, mRNA is degraded rapidly within the 
cell, making transmission of SARS-CoV-2 mRNA to the fetus very 
unlikely.[30] While no mRNA vaccines have been purposefully used 
in pregnant women in trial settings, animal studies on the Moderna 
vaccine reported no effects on fetal development in rats given the 
vaccine prior to conception and during pregnancy.[31] A common 
adverse effect associated with vaccination with both of the mRNA 
SARS-CoV-2 vaccines is a transient fever >38°C in up to 16% of 
vaccinees.[28,29] Fever has been associated with adverse pregnancy 
outcomes, and use of antipyretics has therefore been suggested by 
the CDC as a means of managing this potential adverse effect in 
pregnancy.[32]
Table 1. Overview of COVID-19 vaccines





Viral vector Granted EUA (or equivalent) in the 
EU, UK and India (among others)
Section 21 review finalised and EUA 
granted by SAHPRA on 22 January 2021
Johnson & Johnson 
(Janssen)
AD26.COV2.S Viral vector Rolling review application submitted 
to the UK
Granted EUA in the EU and USA
Rolling review submission to 
SAHPRA – currently under review
Rolled out as part of the Sisonke 
Vaccine Programme
Pfizer/BioNTech BNT-162b2 mRNA Granted EUA (or equivalent) in 
the UK and USA by the WHO and 
provisionally in the EU
Submitted to SAHPRA – currently 
under review
Moderna mRNA-1273 mRNA Granted EUA (or equivalent) in the 
UK, USA and EU
No submission to SAHPRA 
Novavax NVX-CoV2373 Recombinant 
protein
Rolling review submitted in the EU, 
USA, UK and Canada
No submission to SAHPRA
EUA = Emergency Use Authorisation; SAHPRA = South African Health Products Regulatory Authority; WHO = World Health Organization.
*As of 15 March 2021.
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Protein vaccines
The Novavax vaccine is a recombinant nanoparticle protein vaccine 
based on the SARS-CoV-2 spike protein.[33] Although pregnant 
women were also excluded from the clinical trials of this vaccine, 
Novavax have gathered safety data in previous trials for an RSV 
vaccine in pregnant women using a similar vaccine platform.[34] In 
addition, protein-based vaccines have been used safely in pregnant 
women for immunisation against influenza and hepatitis B, and as 
a result there are fewer safety concerns regarding the use of these 
vaccines in pregnancy in comparison with other vaccine platforms.
Rationale for vaccinating pregnant 
women
Maternal vaccination decreases the risk of maternal illness and takes 
advantage of transplacental transfer of IgG to the fetus in utero and 
IgA transfer to the neonate in breastmilk.[35,36] This antibody transfer 
protects the infant in the first few months of life when the immune 
system is immature and the infant is at risk of significant infection 
before the first scheduled vaccines are administered.
Evidence exists for benefits of influenza vaccination in pregnancy: 
vaccination reduces maternal mortality due to influenza, as well 
as preterm birth and intrauterine growth restriction. In addition, 
maternal vaccination confers protection against influenza in infants 
up to 6 months of age.[37] Importantly, when given in pregnancy, 
influenza vaccination is safe.[38] The influenza vaccine has been shown 
to provide partial protection in both HIV-negative and HIV-positive 
pregnant women and their infants in the SA setting and, along with 
tetanus toxoid, is offered to pregnant women during the antenatal 
period in SA during March and April in anticipation of the influenza 
season.[39,40] Furthermore, and possibly owing to the reduction in viral 
pneumonia, the risk of pertussis pneumonia appears to be reduced by 
50% following influenza vaccination.[41]
Vaccines against tetanus and pertussis, among others, have also 
been shown to reduce infant morbidity and mortality when used 
antenatally.[42] In a recent systematic review, the combined tetanus, 
diphtheria and pertussis vaccine was safe when given in the second 
or third trimester of pregnancy.[43] Maternal pertussis vaccination is 
not yet included in SA guidelines, but maternal vaccination is more 
effective than cocooning strategies aimed at immunising all close 
contacts of the newborn.[44]
Vaccinating pregnant women against COVID-19 may have a 
similar benefit in reducing maternal morbidity and mortality, 
although more trial and real-world data are needed. Clinical trials 
of current vaccine candidates have shown a significant effect in 
prevention of severe COVID-19 in non-pregnant women, and it 
is likely that this protection would extend to vaccinated pregnant 
women.[24,28,29] Maternal vaccination may well also reduce neonatal 
morbidity and mortality through passive immunisation of the fetus. 
Supporting this hypothesis, a recent preprint has shown evidence of 
transfer of SARS-CoV-2-specific antibodies in cord blood following 
SARS-CoV-2 maternal vaccination.[45]
Ethical considerations regarding the 
exclusion of pregnant women from 
COVID-19 vaccine trials
Despite early calls for vaccine manufacturers to include pregnant 
women in COVID-19 vaccine trials, they were excluded from the 
initial trials of the vaccines reported on here.[46-49] The exclusion 
of women from clinical trials on the basis of pregnancy alone is 
contentious. While including pregnant women in the study of new 
vaccines could potentially cause harm, exclusion from such studies 
may also have harmful consequences due to the lack of essential 
knowledge acquired concerning the use of such vaccines in preg-
nancy. Pregnant women and their fetuses deserve access to safe and 
effective evidence-based care. The autonomy of the pregnant woman 
and her ability to weigh up the risks and benefits of participation in 
clinical trials should be considered and respected. Pregnant women 
should be afforded the same opportunity to participate as non-
pregnant individuals, always considering the wellbeing of the fetus 
and the potential for teratogenicity when making these decisions. 
Women should be given the opportunity to discuss concerns with 
their healthcare provider and the trial team and thereafter make an 
informed decision regarding participation.
Future studies are planned to investigate the use of COVID-19 
vaccines in pregnant participants, but some limited data on their safety 
in pregnancy exist.[50,51] A number of trials have reported outcomes on 
women who became pregnant during the trial period, although these 
women accounted for <0.1% of total trial participants. [31,52-54] The 
Moderna and Pfizer vaccine trials reported 13 and 23 pregnancies, 
respectively, with a single miscarriage in the placebo group in both 
trials, while the AstraZeneca trial reported 21 pregnancies with 
2 miscarriages in the vaccine group and 3 in the placebo group. [31,52,53] 
J&J reported 8 pregnancies in their vaccine trial, with a single 
miscarriage in each group.[54] Registries that include pregnant and 
breastfeeding women who have received COVID-19 vaccines, such as 
one established by the University of Washington, are important tools 
to monitor long-term outcomes in this patient group.[55] The CDC’s 
v-safe ‘after-vaccination health checker’ has had >16 000 pregnancies 
reported to it as of 16 February 2021.[56]
Recommendations on vaccinating 
pregnant women
In contrast to guidance from the SA National Department of Health, 
the South African Society of Obstetricians and Gynaecologists has 
recommended that pregnant and breastfeeding women at high risk 
of contracting COVID-19 (e.g. healthcare workers) consider having 
COVID-19 vaccination.[57] This guidance is in keeping with that 
offered by a number of international societies (Table 2), despite vaccine 
manufacturers advising against vaccination of pregnant women owing 
to the lack of clinical data.[46-48,58,59] The WHO has suggested that 
pregnant women who are at high risk of exposure, such as healthcare 
workers, and those at risk of severe disease because of comorbidities 
may be vaccinated with the Moderna vaccine after consultation with 
their healthcare provider.[60,61] The Health Services Executive in Ireland 
has recommended vaccination for all pregnant women between 14 and 
33 weeks’ gestation, whereas the Royal Australian and New Zealand 
College of Obstetricians and Gynaecologists recommends against 
routine vaccination of pregnant women in view of the low levels of 
community transmission in those countries.[49]
Conclusions
It is becoming clear that pregnant women are at increased risk of 
severe COVID-19 resulting in increased maternal morbidity and 
mortality and poor pregnancy outcomes. Pregnant women have 
been excluded from trials investigating vaccines against COVID-19, 
and as such safety data on the use of these vaccines in pregnancy are 
lacking. While the theoretical benefit of maternal vaccination may 
outweigh the known risks associated with COVID-19 in pregnancy, 
pregnant and breastfeeding women have the right to autonomy and 
should be given the choice to vaccinate by making an informed 
decision in consultation with their healthcare provider, using the 
data available.
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